147 related articles for article (PubMed ID: 32115956)
1. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB
J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.
Liu H; Wang Q; Huang Y; Deng J; Xie X; Zhu J; Yuan Y; He YM; Huang YY; Luo HB; He X
Eur J Med Chem; 2022 Nov; 242():114631. PubMed ID: 35985255
[TBL] [Abstract][Full Text] [Related]
3. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.
Huang YY; Deng J; Tian YJ; Liang J; Xie X; Huang Y; Zhu J; Zhu Z; Zhou Q; He X; Luo HB
J Med Chem; 2021 Sep; 64(18):13736-13751. PubMed ID: 34520193
[TBL] [Abstract][Full Text] [Related]
4. Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats.
Jabaris SG; Sumathy H; Kumar RS; Narayanan S; Thanikachalam S; Babu CS
Eur J Pharmacol; 2015 Jan; 746():138-47. PubMed ID: 25446433
[TBL] [Abstract][Full Text] [Related]
5. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
6. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
McDonough W; Aragon IV; Rich J; Murphy JM; Abou Saleh L; Boyd A; Koloteva A; Richter W
FASEB J; 2020 Sep; 34(9):12533-12548. PubMed ID: 32738081
[TBL] [Abstract][Full Text] [Related]
7. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP
ACS Chem Neurosci; 2017 Jan; 8(1):135-146. PubMed ID: 27690383
[TBL] [Abstract][Full Text] [Related]
9. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
11. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
Thevis M; Krug O; Schänzer W
Rapid Commun Mass Spectrom; 2013 May; 27(9):993-1004. PubMed ID: 23592202
[TBL] [Abstract][Full Text] [Related]
12. A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[
Takano A; Uz T; Garcia-Segovia J; Tsai M; Lahu G; Amini N; Nakao R; Jia Z; Halldin C
Mol Imaging Biol; 2018 Aug; 20(4):615-622. PubMed ID: 29441434
[TBL] [Abstract][Full Text] [Related]
13. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
14. Novel Roflumilast analogs as soft PDE4 inhibitors.
Boland S; Alen J; Bourin A; Castermans K; Boumans N; Panitti L; Vanormelingen J; Leysen D; Defert O
Bioorg Med Chem Lett; 2014 Sep; 24(18):4594-4597. PubMed ID: 25149511
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the therapeutic index of a novel phosphodiesterase 4B-selective inhibitor over phosphodiesterase 4D in mice.
Suzuki O; Mizukami K; Etori M; Sogawa Y; Takagi N; Tsuchida H; Morimoto K; Goto T; Yoshino T; Mikkaichi T; Hirahara K; Nakamura S; Maeda H
J Pharmacol Sci; 2013; 123(3):219-26. PubMed ID: 24152964
[TBL] [Abstract][Full Text] [Related]
16. Discovery of oral and inhaled PDE4 inhibitors.
Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
[TBL] [Abstract][Full Text] [Related]
17. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
[TBL] [Abstract][Full Text] [Related]
18. GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Rutter AR; Poffe A; Cavallini P; Davis TG; Schneck J; Negri M; Vicentini E; Montanari D; Arban R; Gray FA; Davies CH; Wren PB
J Pharmacol Exp Ther; 2014 Jul; 350(1):153-63. PubMed ID: 24784567
[TBL] [Abstract][Full Text] [Related]
19. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.
Lin Y; Ahmed W; He M; Xiang X; Tang R; Cui ZN
Eur J Med Chem; 2020 Dec; 207():112795. PubMed ID: 33002845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
